Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Rating) has been assigned an average recommendation of “Buy” from the twelve ratings firms that are covering the stock, Marketbeat reports. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average twelve-month price target among analysts […]
Immatics (NASDAQ:IMTX – Get Rating) and Kymera Therapeutics (NASDAQ:KYMR – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends. Profitability This table compares Immatics and Kymera Therapeutics’ net margins, […]
Agenus (NASDAQ:AGEN – Get Rating) and Kymera Therapeutics (NASDAQ:KYMR – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, analyst recommendations, dividends and profitability. Analyst Recommendations This is a summary of current ratings and […]
Brokerages expect Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Rating) to report $17.36 million in sales for the current quarter, according to Zacks. Five analysts have made estimates for Kymera Therapeutics’ earnings, with the lowest sales estimate coming in at $15.43 million and the highest estimate coming in at $20.00 million. Kymera Therapeutics reported sales of […]